Idioma:

Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Szabo, Zsolt ; Mena, Esther ; Rowe, Steven P. ; Plyku, Donika ; Nidal, Rosa ; Eisenberger, Mario A. ; Antonarakis, Emmanuel S. ; Fan, Hong ; Dannals, Robert F. ; Chen, Ying ; Mease, Ronnie C. ; Vranesic, Melin ; Bhatnagar, Akrita ; Sgouros, George ; Cho, Steve Y. ; Pomper, Martin G.

Molecular imaging and biology, 2015-08, Vol.17 (4), p.565-574 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível

Citações Citado por

Enviar para

Título:
Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
Autor: Szabo, Zsolt ; Mena, Esther ; Rowe, Steven P. ; Plyku, Donika ; Nidal, Rosa ; Eisenberger, Mario A. ; Antonarakis, Emmanuel S. ; Fan, Hong ; Dannals, Robert F. ; Chen, Ying ; Mease, Ronnie C. ; Vranesic, Melin ; Bhatnagar, Akrita ; Sgouros, George ; Cho, Steve Y. ; Pomper, Martin G.
Assuntos: Aged ; Antigens, Surface - metabolism ; Feasibility Studies ; Glutamate Carboxypeptidase II - metabolism ; Humans ; Imaging ; Lysine - adverse effects ; Lysine - analogs & derivatives ; Lysine - pharmacokinetics ; Lysine - therapeutic use ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Positron-Emission Tomography - methods ; Prostate - metabolism ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - metabolism ; Radiology ; Radiometry ; Research Article ; Tissue Distribution ; Urea - adverse effects ; Urea - analogs & derivatives ; Urea - pharmacokinetics ; Urea - therapeutic use
É parte de: Molecular imaging and biology, 2015-08, Vol.17 (4), p.565-574
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Purpose Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [ 18 F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer. Procedures Biodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM. Results No major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUV max up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [ 18 F]DCFPyL was 0.0139 mGy/MBq or 5 mGy (0.5 rem) from an injected dose of 370 MBq (10 mCi). Conclusions [ 18 F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [ 18 F]DCFPyL is similar to that from other PET radiotracers.
Editor: New York: Springer US
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Szabo, Zsolt ; Mena, Esther ; Rowe, Steven P. ; Plyku, Donika ; Nidal, Rosa ; Eisenberger, Mario A. ; Antonarakis, Emmanuel S. ; Fan, Hong ; Dannals, Robert F. ; Chen, Ying ; Mease, Ronnie C. ; Vranesic, Melin ; Bhatnagar, Akrita ; Sgouros, George ; Cho, Steve Y. ; Pomper, Martin G.

New York: Springer US

Buscando em bases de dados remotas. Favor aguardar.